Remove 2016 Remove Digital Health Remove Drug Development Remove Health Data
article thumbnail

Teladoc Livongo merger: what went wrong with the 'one-stop shop for virtual care' strategy?

Lloyd Price

The market for digital health is maturing. When the Teladoc Livongo merger was announced in 2020, the market for digital health was still in its early stages. However, the market has matured since then, and there are now a number of other digital health companies competing with Teladoc.

article thumbnail

6 challenges healthtech can help us tackle – Pt.2

Digital Health Global

Wearable monitoring devices, genomics, and AI play vital roles in this transformation, enabling personalized interventions and collective health data sharing for research. There are three main advantages to the use of AI in drug development: width of research, speed of execution, low costs. DiMasi, H.G.

article thumbnail

The outlook for healthcare in 2022

Waracle

London health tech startups secured a staggering $2.9 billion in funding, and the fastest-growing subsector in London is remote monitoring and wearables, raising $345 million in 2021, which is 20 times more than what it was in 2016. . In fact, Exscientia stands by the claim that all drugs in the future will be made using AI. .